At the American Urological Association's 2025 Annual Meeting in Las Vegas, Dr. Félix Guerrero-Ramos (ES) presented the first results from cohort 4 of the SunRISe-1 study, assessing TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG) - unresponsive papillary-only high-risk non-muscle-invasive bladder cancer. In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Guerrero-Ramos about the study’s design, a detailed discussion of the results, comparisons with other trials such as BOND-003, and the implications for clinical practice. For more updates on bladder cancer, please visit our educational platform UROONCO BCa . For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts , Spotify , EAU YouTube channel .
